Dynamic contrast-enhanced MR imaging findings of bone metastasis in patients with prostate cancer

Kayhan, Arda; Yang, Cheng; Soylu, Fatma Nur; Lakadamyalı, Hatıce; Sethi, Ila; Karczmar, Gregory S.; Stadler, Walter M.; Oto, Aytekin

doi:10.4329/wjr.v3.i10.241

Cited by 24 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gradient echo or susceptibility-weighted imaging sequences could be performed to assess this with greater sensitivity . Often, MBD is associated with increased cellularity and therefore demonstrates restricted diffusion on DWI [ 39 ] and varied but increased contrast enhancement following gadolinium administration [ 46 ]. …”

Section: Primary Imaging and The Current Imaging Repertoirementioning

confidence: 99%

See 1 more Smart Citation

State-of-the-art imaging for diagnosis of metastatic bone disease

Isaac

Dalili

et al. 2020

Radiologe

View full text Add to dashboard Cite

Table 1 Epidemiological indicators: total number of cancer cases in Germany in 2013 (modified according to [21]) New cases Women Men Death Women Men Absolute number 229,920 252,550 Absolute number 101,779 121,314 Mean age at diagnosis 67.2 68.3 Mean age at diagnosis 74.3 73.3 Raw rate 558.4 639.9 Raw rate 247.2 307.7 Age-standardized rate a 351.2 434.1 Age-standardized rate a 126.7 196.5 Current trend +0.8%-0.5% Current trend-0.7%-1.2% Age-standardized rate a 327.9 447.6 Age-standardized rate a 126.8 211.8 Prognosis for 2020 (absolute number) 244,100 274,900 Prognosis for 2020 (absolute number)-0.8%-1.5%

show abstract

Section: Primary Imaging and The Current Imaging Repertoirementioning

confidence: 99%

“…Often, MBD is associated with increased cellularity and therefore demonstrates restricted diffusion on DWI [ 39 ] and varied but increased contrast enhancement following gadolinium administration [ 46 ].…”

Section: Primary Imaging and The Current Imaging Repertoirementioning

confidence: 99%

State-of-the-art imaging for diagnosis of metastatic bone disease

Isaac

Dalili

et al. 2020

Radiologe

View full text Add to dashboard Cite

show abstract

“…Technical limitations of data acquisition can limit the anatomic extent of coverage by a given imaging method. For example, dynamic contrast enhancement magnetic resonance imaging (DCE‐MRI) cannot be used to evaluate the entire skeleton because of the need to perform a stationary series of rapid volume acquisitions before and after bolus intravenous contrast medium administration . Since no single imaging method can evaluate all aspects of metastatic bone disease, a comprehensive evaluation of the skeleton often requires a multimodal approach.…”

Section: Skeletal Therapy Assessment Toolsmentioning

confidence: 99%

“…Ultrashort TE (UTE) sequences can also evaluate trabecular bone structure in healthy bone and metastatic disease . A number of studies have evaluated bone marrow vascularization using DCE‐MRI techniques . Diffusion‐weighted imaging (DWI) is increasingly being used because of its sensitivity to bone marrow cellularity, the relative proportions of fat and marrow cells, water content, and bone marrow perfusion .…”

Section: Skeletal Therapy Assessment Toolsmentioning

confidence: 99%

Therapy monitoring of skeletal metastases with whole-body diffusion MRI

Padhani

Makris

Gall

et al. 2014

J. Magn. Reson. Imaging

106

View full text Add to dashboard Cite

Current methods of assessing tumor response at skeletal sites with metastatic disease use a combination of imaging tests, serum and urine biochemical markers, and symptoms assessment. These methods do not always enable the positive assessment of therapeutic benefit to be made but instead provide an evaluation of progression, which then guides therapy decisions in the clinic. Functional imaging techniques such as whole-body diffusion magnetic resonance imaging (MRI) when combined with anatomic imaging and other emerging "wet" biomarkers can improve the classification of therapy response in patients with metastatic bone disease. A range of imaging findings can be seen in the clinic depending on the type of therapy and duration of treatment. Successful response to systemic therapy is usually depicted by reductions in signal intensity accompanied by apparent diffusion coefficient (ADC) increases. Rarer patterns of successful treatment include no changes in signal intensity accompanying increases in ADC values (T2 shine-through pattern) or reductions in signal intensity without ADC value changes. Progressive disease results in increases in extent/intensity of disease on high b-value images with variable ADC changes. Diffusion MRI therapy response criteria need to be developed and tested in prospective studies in order to address current, unmet clinical and pharmaceutical needs for reliable measures of tumor response in metastatic bone disease.

show abstract

“…In one study [35 & ] comparing DCE-MRI derived parameters in prostate cancer and healthy patients, both quantitative and semiquantitative parameters were able to provide a cutoff to distinguish bone metastases from normal bone marrow, with further studies confirming lower values in normal bone marrow [36]. Unfortunately, standard MRI is not able to differentiate tumour cells until much of the normal marrow has been replaced by malignant marrow.…”

Section: Dynamic Contrast-enhanced-mrimentioning

confidence: 99%